Inhibition of Coxsackie B3 Virus Induced Myocarditis in Mice by 2-(3,4-Dichlorophenoxy)-5-Nitrobenzonitrile

Journal of Medical Virology

Volumn 72, Issue 2, 2004, Pages 263-267

  Padalko, Elizaveta ^a   Verbeken, Erik ^a   De Clercq, Erik ^b   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Antiviral; Cox sackie; Enterovirus; Myocarditis

Indexed keywords

2 (3,4 DICHLOROPHENOXY) 5 NITROBENZONITRILE; ANTIVIRUS AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; COXSACKIE VIRUS B; COXSACKIE VIRUS B3; EARLY DIAGNOSIS; FIBROBLAST; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; HYPOTHESIS; MALE; MOUSE; NONHUMAN; PICORNAVIRUS; VIRUS LOAD; VIRUS MYOCARDITIS; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; ENTEROVIRUS B, HUMAN; ENTEROVIRUS INFECTIONS; HUMANS; MICE; MICE, INBRED C3H; MYOCARDITIS; NITRILES; VERO CELLS; VIRUS REPLICATION;

ANIMALIA; ENTEROVIRUS; HUMAN ENTEROVIRUS B; MURINAE;

EID: 0347064337     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10570     Document Type: Article

References (18)

1. Baboonian C, Treasure T. 1997. Meta-analysis of the association of enteroviruses with human heart disease. Heart 78:539-543.
2. Baboonian C, Davies MJ, Booth JC, McKenna WJ. 1997. Coxsackie B viruses and human heart disease. Curr Top Microbiol Immunol 223:31-52.
3. Bauer S, Gottesman G, Sirota L, Litmanovitz I, Ashkenazi S, Levi I. 2002. Severe Coxsackie virus B infection in preterm newborns treated with pleconaril. Eur J Pediatr 161:491-493.
4. Gebhard JR, Perry CM, Harkins S, Lane T, Mena I, Asensio VC, Campbell IL, Whitton JL. 1998. Coxsackievirus B3-induced myocarditis: Perforin exacerbates disease, but plays no detectable role in virus clearance. Am J Pathol 153:417-428.
5. Horwitz MS, La Cava A, Fine C, Rodrigez E, Ilic A, Sarvetnick N. 2000. Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nat Med 6:693-697.
6. Kawai C. 1999. From myocarditis to cardiomyopathy: Mechanisms of inflammation and cell death: Learning from the past for the future. Circulation 99:1091-1100.
7. Kishimoto C, Crumpacker CS, Abelmann WH. 1988. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets. J Am Coll Cardiol 12:1334-1341.
8. Leyssen P, Charlier N, Paeshuyse J, De Clercq E, Neyts J. 2003. Prospects for antiviral therapy. In: Chambers TJ, Monath TP, editors. The flaviviruses: Current molecular aspects of evolution, biology and disease protection. A volume of advances in virus research. XXX: Academic Press. (In press).
9. Liekens S, Verbeken E, Vandeputte M, De Clercq E, Neyts J. 1999. A novel animal model for hemangiomas: Inhibition of hemangioma development by angiogenesis inhibitor TNP-470. Cancer Res 59: 2376-2383.
10. Martino TA, Liu P, Petric M, Sole MJ. 1995. Enteroviral myocarditis and dilated cardiomyopathy: A review of clinical and experimental studies. In: Rotbart HA, editor. Human enterovirus infections. Washington, DC: American Society for Microbiology Press.
11. O'Connel JB. 1987. The role of myocarditis in end-stage dilated cardiomyopathy. Tex Heart Inst 14:268-275.
12. Padalko E, Nuyens D, Verbeken E, Aerts JL, De Clercq E, Carmeliet P, Neyts J. 2003a. The inter-feron inducer Ampligen® [poly(I)-poly(C12U)] markedly protects against Coxsackie B3 virus-induced myocarditis in mice. Antimicrobial Agents and Chemotherapy (in press).
13. Pevear DC, Tull TM, Seipel ME, Groarke JM. 1999. Activity of Pleconaril against enteroviruses. Antimicrob Agents Chemother 43:2109-2115.
14. Powers RD, Gwaltney JM, Jr., Hayden FG. 1982. Activity of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860) against picornaviruses in vitro. Antimicrob Agents Chemother 22:639-642.
15. Rose NR. 2000. Viral damage or 'molecular mimicry' - Placing the blame in myocarditis. Nat Med 6:631-632.
16. Sole MJ, Liu P. 1993. Viral myocarditis: A paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol 22:99A-105A.
17. Torney HL, Dulworth JK, Steward DL. 1982. Antiviral activity and mechanism of action of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860). Antimicrob Agents Chemother 22:635-638.
18. Woodruff J. 1980. Viral myocarditis. Am J Pathol 101:427-479.